

DAESUNG MAREF CO., LTD.

(HQ & 1st Factory) 298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, Korea

has been assessed and certified as meeting the requirements of

Directive 93/42/EEC on medical devices, Annex II (excluding Section 4)

For the following products

The scope of registration appears on page 2 of this certificate.

This certificate is valid from 05 November 2020 until 10 July 2023
and remains valid subject to satisfactory surveillance audits.

Issue 3. Certified since 10 July 2015
and first certified by SGS Belgium NV since 16 December 2019

This is a multi-site certification.
Additional site details are listed on subsequent pages

Certification is based on reports numbered KR/SEL Y-PC/14403

Authorised by



SGS Belgium NV, Notified Body 1639

SGS House Noorderlaan 87 2030 Antwerp Belgium
t +32 (0)3 545-48-48 f +32 (0)3 545-48-49 www.sgs.com

LPMD5007 - Certificate CE1639 Annex II-4_EN rev. 02

Page 1 of 2



DAESUNG MAREF CO., LTD.

Directive 93/42/EEC on medical devices, Annex II (excluding Section 4)

Issue 3

Detailed scope

**Intermittent Pneumatic Compression System for the treatment
and prevention of lymphedema (Model: LF900, MK400L);**

**Digital Pneumatic Tourniquet System for the hemostasis
during surgery (Model: DTS-3000);**

**Intermittent Pneumatic Compression System for the prevention
of deep vein thrombosis and pulmonary embolism after surgery
(Model: DVT-2600, DVT-4000S, DVT-PRO)**

Where the above scope includes class III medical device(s), a valid EC Design Examination Certificate according to Annex II (Section 4) is a mandatory requirement for each device in addition to this certificate to place that device on the market.

Additional facilities

**(Warehouse) 25-22, Hyundaiakia-ro,
Paltan-myeon, Hwaseong-si, Gyeonggi-do, Korea
(2nd Factory) 1F, 298-21, Gongdan-ro, Gunpo-si, Gyeonggi-do, Korea**



Corrigendum to Certificate KR19/81826209

DAESUNG MAREF CO., LTD.

(HQ & 1st Factory) 298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, Korea

Scope:

Intermittent Pneumatic Compression System for the treatment and prevention of lymphedema (Model: LF900, MK400L);

Digital Pneumatic Tourniquet System for the hemostasis during surgery (Model: DTS-3000);

Intermittent Pneumatic Compression System for the prevention of deep vein thrombosis and pulmonary embolism after surgery (Model: DVT-2600, DVT-4000S, DVT-PRO)

This corrigendum is only valid together with accompanying 93/42/EEC certificate
Issue 3

<u>Correction Date</u>	<u>Correction</u>
Change approved by SGS on 05 December 2022	Removal the device 'Digital Pneumatic Tourniquet System for the hemostasis during surgery (Model: DTS-3000)' in MDD scope

Authorised by

Global Medical Devices Certification Manager

SGS Belgium NV, Notified Body 1639

SGS House Noorderlaan 87 2030 Antwerp Belgium
t +32 (0)3 545-48-48 f +32 (0)3 545-48-49 www.sgs.com

LPMD5105 – Corrigendum to Certificate

Page 1 of 1

SGS Belgium NV

Certification and Business Enhancement Maatschappelijke Zetel/Siège Social:
Noorderlaan 87 B-2030 Antwerpen/Anvers
t +32 (0)3 545 48 48 f +32 (0)3 545 48 49
www.be.sgs.com

Member of the SGS Group

RPR Antwerp VAT – BE 0404.882.750 Citibank BE87 5701 3412 5594



DAESUNG MAREF CO., LTD.
(Head Office Laboratory, Service Center & 2nd Factory)
298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, 15809, Republic of Korea

(1st Factory)
32-33, LS-ro 91beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, 14119, Republic of Korea
SRN: KR-MF-000008616

March 25, 2025

Confirmation Letter Reference: CLNB1639 - KR/SEL/Y-PC/14403

To whom it may concern,

Confirmation of receipt of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.

This letter confirms that, SGS Belgium NV, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 1639 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer

Manufacturer

DAESUNG MAREF CO., LTD.
(Head Office Laboratory, Service Center & 2nd Factory)
298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, 15809, Republic of Korea

(1st Factory)
32-33, LS-ro 91beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, 14119, Republic of Korea
SRN: KR-MF-000008616

Authorized representative

KTR Europe GmbH
Mergenthalerallee, 77
65760 Eschborn
Germany
SRN: DE-AR-000005685

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below . Table 1 identifies the devices which an MDR application has been

received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that:

- The manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry;
- The certificates expired after 26th May 2021 by course of time and were valid at the date of their expiry neither having been suspended nor withdrawn.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3 of MDR (as amended by EU 2023/607), are shown below:

- 26th May 2026 for Class III custom-made implantable devices
- 31st December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31st December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31st December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body SGS Belgium NV NB1639,



Pp[Sean Kelly]
Virginie SILORET
Global Medical Device Certification Manager
Email: Virginie.siloret@sgs.com
Phone: +41 22 739 98 58

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	MDD Device name (please indicate if correlation with MDR denomination is not obvious)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Intermittent Pneumatic Compression System for the prevention of deep vein thrombosis and pulmonary embolism after surgery (Models: DVT-4000S, DVT-2600) Basic UDI-DI: 880931567DVTSD	Class IIa		N/A	CE1639 KR19/81826209
Intermittent Pneumatic Compression System for the treatment and prevention of lymphedema (Model: LF900, MK400L) Basic UDI-DI: 880931567IPCRJ	Class IIa		N/A	CE1639 KR19/81826209
Circulating-fluid thermal compression therapy system control unit (Model: CTC-7)	Class IIa		N/A	CE0068 0068/QCO-DM/174-2020

Device name or Basic UDI-DI	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	MDD Device name (please indicate if correlation with MDR denomination is not obvious)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Basic UDI-DI: 880931567CTCQY				

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A			

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2023/07/12	Version 1	Initial issue
2024/05/01	Version 2	Added 'CTC-7' transferred from another NB
2024/05/20	Version 3	Corrected contract number
2025/03/25	Version 4	Corrected the address